Blog

Evandro de Azambuja: The prognostic value of residual disease RD biology and gene expression after NAT in HER2-positive EBC

Evandro de Azambuja/congressooncologia.com.br

Jan 29, 2025, 10:11

Evandro de Azambuja: The prognostic value of residual disease RD biology and gene expression after NAT in HER2-positive EBC

Evandro de Azambuja, BSMO President 2023-2026, shared on LinkedIn:

“Our paper highlighting the prognostic value of residual disease (RD) biology and gene expression after NAT in patients with HER2-positive EBC – intrinsic subtypes at baseline provide more prognostic information while immune gene expression signatures provide more prognostic information in RD.”

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC) – Annals of Oncology

Authors: A. Fernandez-Martinez, M. Tanioka, S.G. Ahn, P. Zagami, T. Pascual, M. Rediti, G. Tang, K.A. Hoadley, D. Venet, N.U. Rashid, P.A. Spears, S. Di Cosimo, E. de Azambuja, A. Choudhury, P. Rastogi, M.N. Islam, J. Cortes, A. Llombart-Cussac, S.M. Swain, C. Sotiriou, A. Prat, C.M. Perou, L.A. Carey

A. Choudhury A. Fernandez-Martinez A. Llombart-Cussac A. Prat C. Sotiriou C.M. Perou cancer D. Venet E. de Azambuja Evandro de Azambuja G. Tang J. Cortes K.A. Hoadley L.A. Carey M. Rediti M. Tanioka M.N. Islam N.U. Rashid OncoDaily Oncology P. Rastogi P. Zagami P.A. Spears S. Di Cosimo S.G. Ahn S.M. Swain T. Pascual

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute